ArticleBMC cancer2020
Clinicopathological characteristics, treatment and prognosis of head & neck small cell carcinoma: a SEER population-based study.
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- Pathological subtype dictates survival and failure pattern in laryngeal neuroendocrine neoplasms: a 15-year single-institution experience.World journal of surgical oncology · 2026Article
- Clinical Characteristics and Prognosis of Neuroendocrine Carcinoma in the Head and Neck: A Single-Institutional Retrospective Analysis.Current oncology (Toronto, Ont.) · 2026Article
- Prognosis Prediction in Head and Neck Squamous Cell Carcinoma by Radiomics and Clinical Information.Biomedicines · 2024Article
- Long-term outcomes and prognosis of neuroendocrine neoplasms of the head and neck: a cohort from a single institution.Journal of cancer research and clinical oncology · 2024Article
- Small-cell carcinoma in the head and neck region: A propensity score-matched analysis of the effect of surgery.PloS one · 2024Article
- A Random Forest Model for Post-Treatment Survival Prediction in Patients with Non-Squamous Cell Carcinoma of the Head and Neck.Journal of clinical medicine · 2023Article
- An online tool for survival prediction of extrapulmonary small cell carcinoma with random forest.Frontiers in oncology · 2023Article
- Head and neck small-cell carcinoma: A multicenter study of 39 cases from 10 institutions.Frontiers in surgery · 2022Article
- A Novel Overall Survival Nomogram Prediction of Secondary Primary Malignancies after Hypopharyngeal Cancer: A Population-Based Study.Journal of oncology · 2022Article
- Malignant Myoepithelioma of the Head and Neck: Demographics, Clinicopathological Characteristics, Treatment, and Prognosis.Frontiers in oncology · 2022Article
- Neuroendocrine Carcinoma of the Larynx and Pharynx: A Clinical and Histopathological Study.Cancers · 2021Article
- Survival and risk factors of adenosquamous carcinoma in the oral and maxillofacial region: a population-based study.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the clinicopathological characteristics of head and neck small cell carcinoma (H&NSmCC) and identify prognostic factors on the basis of the Surveillance, Epidemiology and End Results (SEER) database.
methodsTotal of 789 primary cases from 1973 to 2016 were included. Univariate and multivariate analyses were performed to identify independent prognostic indicators. An H&NSmCC-specific nomogram was constructed and compared with the AJCC staging system by calculating the time-dependent area under the curve (AUC) of the receiver operating characteristic (ROC) curves.
resultsThe incidence of H&NSmCC peaked during the period of 50 to 70 years old, and the most frequent location was the salivary gland. The 5-year disease specific survival (DSS) was 27%. In the multivariate survival analysis, AJCC III + IV stage [HR = 2.5, P = 0.03, I + II stage as Ref], positive N stage [HR = 1.67, P = 0.05, negative N stage as Ref], positive M stage [HR = 4.12, P = 0.000, negative M stage as Ref] and without chemotherapy [HR = 0.56, P = 0.023, received chemotherapy as Ref] were independently associated with DSS. The H&NSmCC-specific nomogram was built based on the independent prognostic indicators. The nomogram demonstrated better predictive capacity than the AJCC staging system for 5-year DSS [(AUC: 0.75 vs 0.634; Harrell's C-index (95% CI): 0.7(0.66-0.74) vs 0.59(0.55-0.62), P < 0.05].
conclusionN stage, M stage, AJCC stage and chemotherapy were independent prognostic indicators included in the prognostic nomogram model, which can better predict the survival of H&NSmCC than the AJCC staging system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.